Development of the Endoscopic Pouch Score for Assessment of Inflammatory Conditions of the Pouch

Contributors

doi:10.1016/j.cgh.2022.04.026

Development of the Endoscopic Pouch Score for Assessment of Inflammatory Conditions of the Pouch

Contributors

Research output: Contribution to journal › Short survey › peer-review

1 Scopus citations

Original language	English
Journal	Clinical Gastroenterology and Hepatology
DOIs	https://doi.org/10.1016/j.cgh.2022.04.026
State	Accepted/In press - 2022

Access to Document

10.1016/j.cgh.2022.04.026

Cite this

@article{6c08e2c7ae6841f99be8424ac70eb003,

title = "Development of the Endoscopic Pouch Score for Assessment of Inflammatory Conditions of the Pouch",

author = "Contributors and Barnes, {E. L.} and Long, {M. D.} and L. Raffals and K. Isaacs and Stidham, {R. W.} and Herfarth, {H. H.} and P. Deepak and P. Beniwal-Patel and M. Kayal and M. Dubinsky and S. Chang and Higgins, {P. D.R.} and Barr, {J. I.} and Y. Jiang and Cross, {R. K.}",

note = "Funding Information: Funding Supported by grants from the Crohn{\textquoteright}s & Colitis Foundation [614963 (ELB)] and the National Institutes of Health [K23DK127157-01 (ELB) and P30DK034987]. PD is supported by a Junior Faculty Development Award from the American College of Gastroenterology and IBD Plexus of the Crohn's and Colitis Foundation . Funding Information: Funding Supported by grants from the Crohn's & Colitis Foundation [614963 (ELB)] and the National Institutes of Health [K23DK127157-01 (ELB) and P30DK034987]. PD is supported by a Junior Faculty Development Award from the American College of Gastroenterology and IBD Plexus of the Crohn's and Colitis Foundation. Conflicts of interest These authors disclose the following: Edward L. Barnes has served as a consultant for AbbVie, Gilead, Pfizer, and Target RWE. Parakkal Deepak has served as a consultant or on an advisory board for Janssen, Pfizer, Prometheus Biosciences, Boehringer Ingelheim, AbbVie, Arena Pharmaceuticals, and Scipher Medicine Corporation and has also received funding under a sponsored research agreement unrelated to the data in the paper from Takeda Pharmaceutical, Arena Pharmaceuticals, Bristol Myers Squibb-Celgene, and Boehringer Ingelheim. Poonam Beniwal-Patel has received honorarium from the Takeda speaker's bureau. Marla Dubinsky has served as a consultant or has received advisory board fees from AbbVie, Arena, BMS, Eli Lilly, Gilead, Janssen, Pfizer, Prometheus Labs, and Takeda; has received grant support from Janssen and AbbVie; and also has had the following relationships: licenser of software: Takeda; co-founder, equity ownership, and board of director for Trellus Health. Shannon Chang has served as a consultant for AbbVie, BMS, and Pfizer. Raymond K. Cross has participated in advisory boards for AbbVie, Bristol Myers Squibb, Janssen, and Pfizer and has served as a consultant for Eli Lilly. Millie D. Long has served as a consultant for AbbVie, UCB, Takeda, Janssen, Pfizer, Salix, Valeant, and Target Pharmasolutions and has received research support from Pfizer and Takeda. Ryan W. Stidham has served as a consultant for AbbVie, Janssen, Merck, Takeda, Gilead, CorEvitas, Eli Lilly, and Evergreen Pharmaceuticals; has research support from AbbVie and Janssen; and has licensed intellectual property to AMI, Inc. Hans H. Herfarth has served as a consultant for Alivio, AMAG, BMS, ExeGI Finch, Gilead, Janssen, Lycera, Merck, Otsuka, Pfizer, PureTech, and Seres and has received research support from Pfizer and Artizan Biosciences. The remaining authors disclose no conflicts.",

year = "2022",

doi = "10.1016/j.cgh.2022.04.026",

language = "English",

journal = "Clinical Gastroenterology and Hepatology",

issn = "1542-3565",

publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Development of the Endoscopic Pouch Score for Assessment of Inflammatory Conditions of the Pouch

AU - Contributors

AU - Barnes, E. L.

AU - Long, M. D.

AU - Raffals, L.

AU - Isaacs, K.

AU - Stidham, R. W.

AU - Herfarth, H. H.

AU - Deepak, P.

AU - Beniwal-Patel, P.

AU - Kayal, M.

AU - Dubinsky, M.

AU - Chang, S.

AU - Higgins, P. D.R.

AU - Barr, J. I.

AU - Jiang, Y.

AU - Cross, R. K.

N1 - Funding Information: Funding Supported by grants from the Crohn’s & Colitis Foundation [614963 (ELB)] and the National Institutes of Health [K23DK127157-01 (ELB) and P30DK034987]. PD is supported by a Junior Faculty Development Award from the American College of Gastroenterology and IBD Plexus of the Crohn's and Colitis Foundation . Funding Information: Funding Supported by grants from the Crohn's & Colitis Foundation [614963 (ELB)] and the National Institutes of Health [K23DK127157-01 (ELB) and P30DK034987]. PD is supported by a Junior Faculty Development Award from the American College of Gastroenterology and IBD Plexus of the Crohn's and Colitis Foundation. Conflicts of interest These authors disclose the following: Edward L. Barnes has served as a consultant for AbbVie, Gilead, Pfizer, and Target RWE. Parakkal Deepak has served as a consultant or on an advisory board for Janssen, Pfizer, Prometheus Biosciences, Boehringer Ingelheim, AbbVie, Arena Pharmaceuticals, and Scipher Medicine Corporation and has also received funding under a sponsored research agreement unrelated to the data in the paper from Takeda Pharmaceutical, Arena Pharmaceuticals, Bristol Myers Squibb-Celgene, and Boehringer Ingelheim. Poonam Beniwal-Patel has received honorarium from the Takeda speaker's bureau. Marla Dubinsky has served as a consultant or has received advisory board fees from AbbVie, Arena, BMS, Eli Lilly, Gilead, Janssen, Pfizer, Prometheus Labs, and Takeda; has received grant support from Janssen and AbbVie; and also has had the following relationships: licenser of software: Takeda; co-founder, equity ownership, and board of director for Trellus Health. Shannon Chang has served as a consultant for AbbVie, BMS, and Pfizer. Raymond K. Cross has participated in advisory boards for AbbVie, Bristol Myers Squibb, Janssen, and Pfizer and has served as a consultant for Eli Lilly. Millie D. Long has served as a consultant for AbbVie, UCB, Takeda, Janssen, Pfizer, Salix, Valeant, and Target Pharmasolutions and has received research support from Pfizer and Takeda. Ryan W. Stidham has served as a consultant for AbbVie, Janssen, Merck, Takeda, Gilead, CorEvitas, Eli Lilly, and Evergreen Pharmaceuticals; has research support from AbbVie and Janssen; and has licensed intellectual property to AMI, Inc. Hans H. Herfarth has served as a consultant for Alivio, AMAG, BMS, ExeGI Finch, Gilead, Janssen, Lycera, Merck, Otsuka, Pfizer, PureTech, and Seres and has received research support from Pfizer and Artizan Biosciences. The remaining authors disclose no conflicts.

PY - 2022

Y1 - 2022

UR - http://www.scopus.com/inward/record.url?scp=85136071112&partnerID=8YFLogxK

U2 - 10.1016/j.cgh.2022.04.026

DO - 10.1016/j.cgh.2022.04.026

M3 - Short survey

C2 - 35568303

AN - SCOPUS:85136071112

SN - 1542-3565

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

ER -